Skip to main content
. 2016 Aug 2;7(34):54157–54173. doi: 10.18632/oncotarget.11022

Figure 5. TAp63 sensitizes BCSCs to therapeutic drugs.

Figure 5

A. Immunoblot analysis of PI3K, P-AKT and AKT, in luminal and basal BCSCs transduced with doxycycline inducible EV, TAp63 or ΔNp63 (iEV, iTAp63 and iΔNp63). β-ACTIN was used as loading control. B. Relative expression levels of PI3K and P-AKT/AKT as in A. Data are expressed as mean ± SD of 3 independent experiments. C. Cell viability analysis of BCSCs transduced as in A and treated with Anastrozole or Docetaxel, alone or in combination with BKM120 up to 72 hours. Data are mean ± SD of 3 independent experiments. D. Relative TAp63 and ΔNp63 expression in luminal and basal BCSCs that survived to the above mentioned treatments. Data are expressed as mean ± SD of 3 independent experiments performed in 3 luminal and 2 basal BCSC lines. E. Scatter plot of drug-resistance related genes in luminal and basal BCSCs as in A. Genes indicated in green and red show fold variation (ΔNp63 vs TAp63) ≥ 3. F. Invasion assay of luminal iEV, iΔNp63 or iΔNp63/shPI3K and basal iEV, iTAp63 or iTAp63/PI3K performed at 72 hours. Data are represented as mean ± SD of 3 independent experiments using 3 luminal and 3 basal BCSCs. G. Flow cytometry analysis of CD44v6 in luminal BCSCs as in F. * indicates P < 0.05, ** indicate P < 0.01 and *** indicate P < 0.001. ns indicates non statistically significant.